BTIG Initiates Coverage On CARISMA Therapeutics With Buy Rating, Announces Price Target of $6
BTIG Initiates Coverage On CARISMA Therapeutics With Buy Rating, Announces Price Target of $6
BTIG以買入評級啓動對CARISMA Therapeutics的報道,宣佈目標股價爲6美元
BTIG analyst Justin Zelin initiates coverage on CARISMA Therapeutics (NASDAQ:CARM) with a Buy rating and announces Price Target of $6.
BTIG分析師賈斯汀·澤林以買入評級啓動了對CARISMA Therapeutics(納斯達克股票代碼:CARM)的報道,並宣佈目標股價爲6美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。